TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05971381

Intervention type: DEVICE
Group type: OTHER
Intervention: RECELL® Autologous Cell Harvesting Device
Description: The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.
Study: NCT05842343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool sample
Description: Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool sample
Description: Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stool sample
Description: Purification by affinity of the IgA coated bacteria from a fecal solution. Genomic analysis of the bacteria for diversity and richness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food intake evaluation
Description: Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food intake evaluation
Description: Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food intake evaluation
Description: Measure (by survey) of food group intake for : lipids /proteins / fibers / carbohydrates
Study: NCT05360732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Alternating FOLFOX and FOLFIRI administered via intravenous infusion. FOLFOX: Oxaliplatin 85 mg/m2 on Day 1; Leucovorin 400 mg/m2 on day 1; 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours. FOLFIRI: Irinotecan 180 mg/m2 on day 1, leucovorin 400 mg/m2, 5-FU: 400 mg/m2 IV push on Day 1 followed by 2400 mg/m2 continuous infusion over 46-48 hours
Study: NCT06401577

Intervention type: DEVICE
Intervention: Dexcom Continuous Glucose Monitor (CGM)
Description: Dexcom Continuous Glucose Monitor which measures and records a participant's serum glucose level
Study: NCT06362837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education intervention on nutrition, gender equity, WASH, sexual and reproductive health rights
Description: Educational training on nutrition, gender equity, WASH, sexual and reproductive health rights will take place in communities (including schools) for women, men, and adolescents

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: school-based iron-folic acid supplement program
Description: The program will help support and promote the school-based programs of weekly iron and folic acid supplementation for adolescent girls, in countries where it is allowed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health service training on equitable access to nutrition, health, and sexual and reproductive services
Description: Training and support activities to make gender-equitable nutrition, health, and sexual and reproductive services in the health facilities

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bio-fortified crops
Description: The program promotes and distributes bio-fortified crops, including orange-fleshed sweet potatoes, rice, beans, and corn
Study: NCT04991025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
Study: NCT05237297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200mg
Study: NCT04991025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab
Description: Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab
Description: Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.
Study: NCT06674005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cucurbita pepo L. Flowers Extract
Description: 2 mg twice per day for 1 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg twice per day for 1 month
Study: NCT06674148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qifangfeixian granules
Description: The experimental group was treated with Qifangfixian granules
Study: NCT06529757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body cooling
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to whole body skin wetting. Skin wetting will be performed by spraying water onto the whole body throughout the exercise bout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-cooling
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modalities.
Study: NCT05232942

Intervention type: OTHER
Intervention: Headache calendar completion
Description: The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
Study: NCT06239025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided Transversus Thoracis Muscle Plane Block
Description: block with ropivacaine 0.5 %, 30 mL
Study: NCT06674148

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group was treated with placebo
Study: NCT06675123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo optional tissue biopsy
Study: NCT05967000

Intervention type: OTHER
Intervention: Preventive heart health and menopause programme
Description: This is a one-stop women's heart and menopausal service in a public hospital led by cardiologists and gynaecologists with a multidisciplinary team. Pre-existing speciality care and services are repackaged, and clinic workflows are reworked to provide more streamlined, convenient, and integrated care. Services encompass:~* Individualised risk assessment, screening, diagnosis, and treatment of CVD.~* Lifestyle education, adjustment, stress management, and counselling.~* Smoking cessation programs.~* Bone health screening, mammogram with access to our co-located gynaecologists and hormone replacement therapy.~* Virtual consults and health coaching.
Study: NCT05558644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single arm for all patients
Description: * tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.
Study: NCT06675123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTK Inhibitor
Description: Given BTK inhibitor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT04767048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral mucosectomy + tonsillectomy
Description: Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillectomy
Description: tonsillectomy (unilateral or bilateral at the choice of the investigator)
Study: NCT06679283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement with a chemo-electric device + PRF
Description: The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed followed by application of PRF clots and membrane. Then, the flap will be closed and sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement with a chemo-electric device alone (control)
Description: The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed. Then the flap will be closed and sutured.
Study: NCT06673901

Intervention type: DEVICE
Intervention: Measurments
Description: Each angle was measured three times, and the mean was calculated to represent the data used for statistical analysis. The assessment position for all measurements was relaxed, comfortable standing position and wearing loose clothing, bare feet, and one foot apart between two feet on a level floor in the same room of the same building, at the same time of day. There was a fixed point in the wall, and the woman was instructed to look at it during the assessment; this point adjusts at the level of her eyes. No specific instructions were provided to the females regarding posture so that measurements during a normal standing position. Data was recorded in a data-collecting sheet.

Intervention type: DEVICE
Intervention: Measurments
Description: Each angle was measured three times, and the mean was calculated to represent the data used for statistical analysis. The assessment position for all measurements was relaxed, comfortable standing position and wearing loose clothing, bare feet, and one foot apart between two feet on a level floor in the same room of the same building, at the same time of day. There was a fixed point in the wall, and the woman was instructed to look at it during the assessment; this point adjusts at the level of her eyes. No specific instructions were provided to the females regarding posture so that measurements during a normal standing position. Data was recorded in a data-collecting sheet.
Study: NCT06675344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Neuro Device
Description: The Apollo Neuro wearable device is an Apple Watch-sized wearable device that delivers vibration at set frequencies , termed transcutaneous vibratory stimulation, or TVS. These low volume sound waves feel like a soothing touch to the skin (TVS) and activate touch receptors. Apollo is controlled via smartphone and worn on the wrist or ankle. The Apollo is fitted with an adjustable band, made of a durable neoprene material with polyester overlays. Participants are asked to wear it daily for a minimum time period for 6 weeks. Users can choose from different modes of vibration, with some being energizing, others relaxing.
Study: NCT05672121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH631
Description: KH631: AAV vector containing a coding sequence for an anti-VEGF protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH631
Description: KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Study: NCT06675344

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The Apollo Neuro is an Apple Watch-sized wearable device that delivers vibration, termed transcutaneous vibratory stimulation, or TVS. The sham device is identical in appearance to the active intervention, but provides a lower frequency vibration that has no known therapeutic benefit.
Study: NCT05672121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH631
Description: KH631: AAV vector containing a coding sequence for an anti-VEGF protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH631
Description: KH631: AAV vector containing a coding sequence for an anti-VEGF protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH631
Description: KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Study: NCT05675371

Intervention type: DEVICE
Intervention: Assessment by the EarliPoint Assessment For Autism Spectrum Disorder
Description: Assessment by The EarliPoint™ Evaluation for Autism Spectrum Disorder (ASD), a medical device which employs Dynamic Quantification of Social-Visual Engagement (DQSVE) to aid clinicians in the diagnosis, assessment, and treatment monitoring of ASD related developmental delays, is a diagnostic tool which measures an individual's visual preferential attention to social information in the environment relative to normative age-specific benchmarks.
Study: NCT05490238

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Description: Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Description: Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Study: NCT05395663

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community health worker
Description: A trained navigator (e.g. OSU Extension staff) will have 3 meetings with the participants in Arm 2. These meetings will be held in person, on the phone, or in zoom.
Study: NCT06684821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Racz catheter
Description: Patients will undergo epidural neuroplasty using Racz catheter during lumber fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic lumber fixation
Description: Patients will undergo classic lumber fixation.
Study: NCT05395663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community health worker
Description: A trained navigator (e.g. OSU Extension staff) will have 3 meetings with the participants in Arm 2. These meetings will be held in person, on the phone, or in zoom.
Study: NCT05379686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucaGen
Description: 150 ug glucagon will be administered to the participants before exercise.
Study: NCT06161441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Administered intravenously (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Administered intravenously (IV) every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV Q3W
Study: NCT06596135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Open-label daily injections of setmelanotide
Study: NCT06686914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) Oil 300mg
Description: Cannabidiol (CBD) Oil 300mg, 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) Oil 150mg
Description: Cannabidiol (CBD) Oil 150mg, 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Placebo Oil, 1 dose
Study: NCT06689995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-immune Capsule
Description: Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days Dose: 100 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days
Study: NCT06687083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal high frequency oscillatory ventilation mode
Description: Preterm neonates who will be allocated will start nHFOV: (CNO, Medin, Germany). nHFOV will be provided via binasal prongs (Size: small, medium, large; Diameter according to its chart; Medin, Germany).~The initial parameters will be mean airway pressure (MAP) of 6 cm H2O (range 6-10), frequency of 8 Hz (range 8-12) and amplitude will be adjusted until infant's chest showed slight oscillations and amplitude will be 7 (range 7-10).~The fraction of inspired oxygen (FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive pressure ventilation mode
Description: Preterm neonates who will be allocated to this group to the nCPAP will be started on a pressure of 6-8 cm H2O, FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter
Study: NCT04837196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)
Study: NCT06161441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV Q3W
Study: NCT04837196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV)
Study: NCT05305911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT-2 inhibitors
Description: SGLT2 inhibitor once daily for six months
Study: NCT06535919

Intervention type: BEHAVIORAL
Intervention: Treatment as Usual
Description: Individuals will receive residential level of care followed by treatment at their partial hospitalization program.
Study: NCT06310213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Pressure Monitor
Description: Modified smart soft contact lens and cap with reader coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Pressure Monitor
Description: Modified smart soft contact lens and cap with reader coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Pressure Monitor
Description: Modified smart soft contact lens and cap with reader coil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Pressure Monitor
Description: Modified smart soft contact lens and cap with reader coil
Study: NCT04837196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV)